BioPerfectus will start the next "golden decade" with a new attitude and adopt a more international logo in a broader commercial market. We aim to create a stronger image that would build on the previous one and accurately describe who we are today: one of the global IVD suppliers with a mission to embrace the world with health.
A batch of Bioperfectus-developed Nucleic Acid Extraction System SSNP-2000B began shipping today to World Health Organization (WHO). The distribution of Bioperfectus SSNP-2000B Nucleic Acid Extraction System will support the development of molecular diagnostics in Africa.
SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.
Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.
SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).
Jiangsu BioPerfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) applied for the clinical evaluation in XYZ Laboratory (XYZ Laboratory 2009 Ranch Rd. 620 N, STE 325, Austin, TX 78732, USA), a CAP accredited CLIA certified high complexity clinical molecular diagnostic laboratory to perform and report the Bioperfectus Monkeypox Virus (MPXV) Fast Real Time PCR Kit.
Human papillomavirus (HPV) is the primary cause of cervical cancer, which is preventable through screening and early treatment. The elimination of cervical cancer has been defined by the WHO as achieving an incidence rate below 4 cases per 100,000 women per year since 2020.
Bioperfectus conducted emergency training to assist frontline healthcare professionals in Uganda using Real-Time PCR diagnostic tools for early detection and control of the latest Ebola outbreak.
BioPerfectus is pleased to launch 𝐀𝐥𝐥𝐟𝐚𝐬𝐭𝐫𝐚 𝐒𝐀𝐑𝐒-𝐂𝐨𝐕-𝟐/𝐅𝐥𝐮𝐀/𝐅𝐥𝐮𝐁/𝐑𝐒𝐕 𝐑𝐞𝐚𝐥 𝐓𝐢𝐦𝐞 𝐏𝐂𝐑 𝐊𝐢𝐭 which has been received the CE marked.
In October 2022, Bioperfectus supplied Monkeypox Virus Real Time PCR kits to Africa CDC to increase the distribution of monkeypox virus test kits to African regions as part of Africa CDC’s continued commitment to addressing the developing emergency.